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Background. The adipose tissue renin-angiotensin system (RAS) contributes to regulation of fat mass and may also impact sys-
temic functions such as blood pressure and metabolism. Methods and results. A panel of mouse models including mice lacking
angiotensinogen, Agt (Agt-KO), mice expressing Agt solely in adipose tissue (aP2-Agt/Agt-KO), and mice overexpressing Agt in
adipose tissue (aP2-Agt) was studied. Total body weight, epididymal fat pad weight, and circulating levels of leptin, insulin, and
resistin were signiﬁcantly decreased in Agt-KO mice, while plasma adiponectin levels were increased. aP2-Agt mice exhibited in-
creased adiposity and plasma leptin and insulin levels compared to wild type (WT) controls. Angiotensinogen and type I Ang II
receptor protein levels were also elevated in kidney of aP2-Agt mice. Conclusion. These ﬁndings demonstrate that alterations in
adiposeRASactivitysigniﬁcantlyimpactbothlocalandsystemicphysiologyinawaythatmaycontributetothedetrimentalhealth
eﬀects of obesity.
Copyright © 2006 Suyeon Kim et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
The RAS plays a central role in blood pressure regulation
and ﬂuid-electrolyte homeostasis, and its disregulation con-
tributestoessentialhypertension[1].AngiotensinII,thema-
jor eﬀector of the RAS, is produced by successive enzymatic
cleavage of the glycoprotein AGT by the enzymes renin and
angiotensin-converting enzyme (ACE). The long-standing
view that AGT, renin, and ACE were exclusive products of
liver,kidney,andthevasculature,respectively,hasbeenmod-
iﬁed in light of discovery that local RAS exist in numerous
tissues [2, 3].
The adipose RAS has been implicated in modulation of
adiposity and overt obesity through its ability to stimulate
both preadipocyte diﬀerentiation and lipogenesis in mature
adipocytes [4, 5]. Angiotensin II enhances lipogenesis by di-
rectly increasing the activity and expression of key lipogenic
enzymes, leading to increased triglyceride synthesis and stor-
age and ultimately “fatter” fat cells. We ﬁrst demonstrated
this response to Ang II in vitro in both murine cell lines
and primary human adipocytes [4]. Subsequently it has been
conﬁrmed in vivo by the ﬁnding that transgenic mice over-
expressing Agt in adipose tissue displayed increased adipos-
ity and total fat mass, without changes in leanness or fat free
mass [6]. Adipose-derived Agt is also released into the cir-
culation where it serves as substrate for conversion to bioac-
tive Ang II, contributes to plasma Ang II levels and increases
blood pressure [6]. Therefore detrimental consequences of
excess Ang II, such as volume expansion and hypertension,
may be exacerbated by conditions that lead to elevated pro-
duction of Agt in adipose tissue [7–10]. Many rodent and
human models indicate that Agt expression in adipose tis-
sue is positively correlated with adipose mass, leading to the
possibilitythattheadiposeRAScontributestoconditionsco-
morbidwithobesity.Angiotensinogenproteinissigniﬁcantly
increased in adipose tissue of numerous rodent models and
human subjects that become obese through varied mecha-
nisms [11–14]. At the other extreme, loss of Ang II produc-
tionbytargeteddeletionoftheAgt genedramaticallyreduces
adipose mass through adipocyte hypotrophy [6, 15, 16].
Data from an assortment of human studies also support a
role for the RAS in regulation of adiposity, but the precise2 Journal of Biomedicine and Biotechnology
relationships vary according to adipose depot sampled, hy-
pertensive status and population variables [17–20].
In this study, we determined the eﬀects of both ubiqui-
tous and adipose tissue-speciﬁc manipulation of Agt levels
on adipose tissue metabolism and systemic indices of insulin
sensitivity. Given the potential role of the adipocyte RAS in
bloodpressureregulation,wealsoexaminedthefeedbackbe-
tween the adipocyte RAS and that in kidney to determine if
adipose changes in Ang II production impacted the RAS in
a distal location known to be important in blood pressure
control.
MATERIALS AND METHODS
Experimentalanimals
The Agt gene was inactivated in the mouse as previously de-
scribed [21]. Transgenic mice (aP2-Agt) overexpressing Agt
in adipose tissue were generated by using a transgenic con-
struct containing an adipocyte-speciﬁc promoter (adipocyte
protein aP2), the mouse Agt c D N A ,a n dap o l y a d e n y l a -
tion site [6]. Mice expressing Agt only in adipose tissue
(aP2-Agt/Agt-KO) were generated by crossing transgenic
mice (aP2-Agt)w i t hAgt-deﬁcient mice (Agt-KO) [6]. Wild-
type (WT; ICR-CD1 strain, Harlen, Gannat, France), Agt-
KO, aP2-Agt/Agt-KO, and aP2-Agt male mice were bred at
the CNRS 6543, Centre de Biochimie at Nice, France, and
shipped to the Department of Nutrition at the University of
Tennessee, Knoxville. Mice were housed 4–6 per cage and fed
a chow (cat # 12450B, Research Diets, New Brunswick, NJ)
and water ad libitum in a 12 : 12h light : dark cycle at con-
stant temperature (22◦C). Body weight was measured and
mice were sacriﬁced at 28 weeks. The epididymal fat pad was
removed and weighed as an index of adiposity. All experi-
ments described were conducted in compliance with the In-
stitutional Animal Care and Use Committee (IACUC) at the
University of Tennessee.
Plasmameasurements
Following an overnight fast, blood was collected by cardiac
puncture for glucose, insulin, leptin, adiponectin, and re-
sistin assays. Plasma leptin and insulin levels were measured
by RIA using mouse leptin and rat insulin RIA kits, respec-
tively,obtainedfromLincoResearch(StCharles,MO).Blood
g l u c o s ec o n c e n t r a t i o n sw e r em e a s u r e du s i n gag l u c o s ea n a -
lyzer (LIFESCAN Co, MI). Plasma adiponectin and resistin
levels were analyzed by ELISA kits obtained from B-Bridge
International, Inc (San Jose, CA) and Phoenix Pharmaceuti-
cals, Inc (Belmont, CA), respectively.
Westernblotanalysis
Proteins were extracted from epididymal fat depots and kid-
neys of WT, Agt-KO, aP2-Agt/Agt-KO, and aP2-Agt mice af-
ter homogenization with a protease inhibitor cocktail and
quantitated by the method of Bradford [22]. Total kidney
protein extracts (∼ 50μg) and epididymal fat pad protein
extracts (∼ 25μg) were electrophoretically separated by
SDS/PAGE on 8–10% running gel and transferred to ni-
trocellulose membranes in transfer buﬀer (20% methanol,
12mM Tri base, 96mM glycine, at pH 8.3), blocked
overnight and incubated with primary polyclonal antibod-
ies detecting AGT (52kDa), type-I Ang II receptor (AGTR1;
47kDa), and type-II Ang II receptor (AGTR2; 46kDa)
(Santa Cruz Biotechnology Inc, Santa Cruz, CA) at 1 :
100, 1 : 200, 1 : 200 dilution, respectively, for 3 hours
at room temperature. Signals were detected using enhanced
chemiluminescence (ICN Biomedicals, Inc, Costa Mesa,
CA). Duplicate gels were prepared and stained with 0.1%
Coomassie blue R250 and then destained in 7% acetic acid,
5% methanol to visualize protein bands for total protein
quantiﬁcation and conﬁrmation of equal protein loading.
The bands obtained in the Western blots were scanned using
Digital Imaging and Analysis Systems (Zero-Dscan software,
Scanalytics Inc, Fairfax, VA).
Statisticalanalysis
All data are expressed as the mean ± SEM. ANOVA was
used to determine between-group diﬀerences in measured
parameters. A signiﬁcant overall F-test was followed by post
hoc comparisons to identify signiﬁcantly diﬀerent groups
using the Bonferroni test for multiple comparisons (SAS,
Carry, NC). Statistical signiﬁcance for all tests was deﬁned
as P<. 05.
RESULTS
EffectofadiposeAgtonfatpadweightand
metabolicparameters
TheeﬀectsofgeneticmanipulationofadiposeAgt expression
on body weight and fat pad mass are shown in Table 1.C o n -
sistentwithpreviousresults[6,15,16],totalbodyweightand
epididymal fat pad mass of Agt-KO mice were signiﬁcantly
lower than those of WT controls. Re-expressing Agt solely
in adipose tissue through the use of an adipocyte-speciﬁc
promoter increased both body and fat pad weights relative
to those of Agt-KO mice (8.5% and 20%, resp), but neither
change was statistically signiﬁcant. It is worth noting that
mice re-expressing Agt only in adipose tissue still exhibited
Agt levelsthatweresigniﬁcantlylowerthaninWTduetolack
of contribution from the endogenous gene, a point reﬂected
in their intermediate levels of both adipose mass (Table 1)
and blood pressure [6]. Although mice overexpressing Agt in
adipose tissue (aP2-Agt) exhibited only a modest diﬀerence
inbodyweight(50g,WTvs52g,aP2-Agt),adipositywassig-
niﬁcantly increased (∼ 50% greater than WT) as evidenced
by the weight of epididymal fat pads (P<. 05).
WenextevaluatedtheeﬀectsofmanipulatingadiposeAgt
productiononplasmaleptin[23]andinsulinlevels,twohor-
mones known to be involved in regulation of energy home-
ostasis [23]. As shown in Table 1, the plasma levels of both
leptin and insulin were signiﬁcantly decreased in Agt-KO
mice compared to those in WT mice. Re-expression of AgtSuyeon Kim et al 3
Table 1: Body weight, fat pad weight, and blood parameters in 28-wk-old WT, Agt-KO, aP2-Agt/Agt-KO, and aP2-Agt mice.
WT Agt-KO aP2-Agt/Agt-KO aP2-Agt
(n = 10) (n = 8) (n = 9) (n = 9)
Body weight (g) 50.0 ±2.4b 35.0 ±0.9a 38.0 ±1.1a 52.0 ±2.8b
Epididymal fat weight (g) 1.1 ±0.18b 0.4 ±0.02a 0.5 ±0.18a 1.6 ±0.15c
Leptin (ng/mL) 5.7 ±0.1b 4.0 ±0.05a 5.5 ±0.06b 8.3 ±0.1c
Insulin (ng/mL) 1.2 ±0.03b 0.6 ±0.03a 0.8 ±0.03a 2.3 ±0.1c
Resistin (ng/mL) 43.4 ±0.7b 8.7 ±1.3a 42.0 ±1.6b 44.3 ±0.1b
Adiponectin (μg/mL) 11.0 ±1.7a 19.1 ±1.1b 11.2 ±2.1a 11.0 ±2.1a
Values with diﬀerent letters are signiﬁcantly diﬀerent (P<. 05); mean ± SEM; n: number of animals.
solely in adipose tissue (aP2-Agt/Agt-KO) restored leptin to
WT levels, despite the lack of a marked increase in adiposity
(Table 1). Insulin levels were modestly (25%) but not sig-
niﬁcantly increased by Agt re-expression in adipose tissue.
Increasing adipose tissue Agt expression beyond wild-type
levels by driving its expression with an adipocyte-speciﬁc
promoter (aP2-Agt) elicited an approximately 50% increase
in plasma leptin levels and almost doubled circulating in-
sulin levels, both of which were statistically signiﬁcant and
which occurred despite similar glucose levels in these (and
all) groups of mice (data not shown).
To further deﬁne potential eﬀects of the adipose RAS
on insulin sensitivity we measured levels of two plasma
adipokines, adiponectin, and resistin, that are widely used
as markers of insulin sensitivity and resistance, respectively
[24–26]. Circulating adiponectin levels increased by 73%
with targeted deletion of Agt, while plasma resistin concen-
tration fell by almost 80% (Table 1). When Agt expression
was restored speciﬁcally to adipose tissue, the levels of both
hormones returned to levels not signiﬁcantly diﬀerent from
WT. However, neither adiponectin nor resistin concentra-
tions were aﬀected by overexpression of Agt in adipose tis-
sue of WT mice, despite considerable hyperinsulinemia and
hyperleptinemia.
EffectsofadiposeAgtonproteinlevelsofRAS
componentsinadiposetissueandkidney
We previously established that blood pressure increases with
adipose expression of Agt and that aP2-Agt mice are hyper-
tensive [6]. Because activation of the renal RAS has been
linked to hypertension [27], and because Ang II can exert
both negative and positive feedback regulation of RAS com-
ponents [27–29], we determined if altering adipose Ang II
activated the intrarenal RAS, which could highlight a possi-
ble mechanism for hypertension displayed in aP2-Agt mice.
We also evaluated the diﬀerential expression and regula-
tion of Ang II receptors within adipose tissue in response
to paracrine changes in Ang II levels. Levels of both AGTR1
and AGTR2 receptors are nearly doubled in adipose tissue
of Agt-KO mice. With re-expression of Agt in adipose tis-
sue, AGTR1 levels completely returned to WT levels while
AGTR2 content was only partially restored, suggesting a
compensatory response to the loss of Ang II (Figure 1).
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Figure 1: Expression of RAS proteins in adipose tissue of WT,
Agt-KO, aP2-Agt/Agt-KO, and aP2-Agt mice. Representative im-
munoblots of AGT, AGTR1, and AGTR2 proteins are shown. A
95kD protein is included as an internal loading control. The bar
graphrepresentsaverageexpressionofRASproteinsfromtwoWest-
ern blots for two diﬀerent experiments (n = 2).
Elevating adipose Agt expression in WT mice is associated
with reduced AGTR2 but normal AGTR1 levels, indicating
a potential feedback mechanism to control AGTR2 recep-
tor expression in accordance with local Ang II production.
Consistent with data in Figure 1, we previously reported that4 Journal of Biomedicine and Biotechnology
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Figure 2: Expression of RAS proteins in the kidney of WT, Agt-KO,
aP2-Agt/Agt-KO, and aP2-Agt mice. Representative immunoblots
of AGT, AGTR1, and AGTR2 proteins are shown. A 75kD protein is
included as an internal loading control. Bars depict mean ± SEM of
the quantitated AGT, AGTR1, and AGTR2 protein bands, indepen-
dently obtained from 3 diﬀerent experiments. Values with diﬀerent
letters are signiﬁcantly diﬀerent (P<. 05); nd: not detected.
overexpressing Agt in adipose tissue increased AGT content
by ∼ 50% over WT [6].
Expression and regulation of these RAS components re-
vealed a distinct proﬁle in kidney (Figure 2). Renal AGT lev-
els were signiﬁcantly elevated when the Agt gene was over-
expressed in adipose tissue, more than doubling the level of
AGT protein found in WT kidneys. This upregulation was
tissue-speciﬁc, as hepatic AGT did not diﬀer between WT
and aP2-Agt animals (data not shown). AGTR1 protein was
reduced in both Agt-KO and aP2-Agt/Agt-KO mice, while
AGTR2 was markedly elevated in both KO models by ap-
proximately 3.5-fold. Overexpression of Agt in adipose tissue
increased renal AGTR1 levels but had no eﬀect on AGTR2.
Therefore AGTR1 protein in kidney appeared to correlate
inversely with circulating levels of AGT. On the other hand,
AGTR2 in kidney responded only to absence or very low lev-
els of circulating AGT, where its upregulation may be im-
portant in correcting the renal morphological defects seen
in Agt-KO animals. Activation of the intrarenal RAS in aP2-
Agt mice, as manifested by upregulation of both AGT and
AGTR1 protein levels, conﬁrms the ability of the adipose
RAS to regulate not only adipocyte physiology but also that
of distal tissues. These eﬀects may cause at least part of the
hypertension observed in this model.
DISCUSSION
We used genetically manipulated mice to determine if alter-
ing activity of the adipose RAS in turn impacts physiological
parameters relevant to obesity and its co-morbidities hyper-
tension and diabetes. This work was driven by our previous
ﬁndingthatadiposeAgt mRNAlevelsvariedconsiderablybe-
tween human patients [30], and by the potential for these
changes to alter sensitivity to both diabetes and hypertension
and thus susceptibility to disease. We ﬁrst examined changes
in adiposity and systemic markers of insulin sensitivity. Mice
lacking Ang II, via targeted deletion of Agt, displayed signiﬁ-
cantly lower plasma levels of insulin, resistin, and leptin and
increasedlevelsofadiponectin,allofwhichsuggestincreased
insulin sensitivity. Therefore the consequences of systemic
lossofAngIIareconsistentwithclinicalandlaboratoryﬁnd-
ings showing that RAS antagonism, either by receptor block-
ade or ACE inhibition, improves insulin sensitivity [31–33]
and increases plasma adiponectin levels [33]. These ﬁndings
diﬀer from those previously reported for the same mice at 6
weeks of age [6], and suggest that the changes in insulin and
leptin status in response to Agt deletion are indirect eﬀects
that develop over time.
Re-expressing Agt exclusively in adipose tissue produced
a modest increase in plasma AGT concentration (∼ 25% of
WT) that was suﬃcient (as reported here) to revert plasma
leptin, adiponectin, and resistin to wild-type levels. These
changes occurred in the absence of signiﬁcant increases in
either insulin levels or fat mass, although a trend for in-
creased adiposity was evident. Restoration of plasma lep-
tin could be attributable to a subtle gain of adipose mass
[23], but it could also be due to direct paracrine eﬀects of
Ang II on transcription of the leptin gene in adipocytes, as
we previously reported for murine 3T3-L1 [4] and primary
human adipocytes [34]. Whether Ang II also directly regu-
lates the expression of other adipokines, such as adiponectin
and resistin, is unknown. If so, subtle changes in adipose
Agt expression could therefore alter insulin sensitivity in a
paracrine or autocrine manner by modifying the production
of adipokines that act on distal insulin-sensitive target tis-
sues.
Elevating the production of Agt in adipose tissue of WT
mice caused both hyperinsulinemia and hyperleptinemia, a
metabolic phenotype that was in many ways the opposite of
Agt deletion. Adiposity increased by ∼ 50% in these trans-
genic mice, consistent with the stimulation of lipogenesis by
Ang II [4] and by Agt overexpression [6]. This change in
adiposity was not reﬂected in body weight, perhaps due to
diﬀerential, depot-speciﬁc actions of Ang II on adipocytes
[35]. It is worth noting that the measure of adiposity em-
ployed here was based solely on the weight of the epididymalSuyeon Kim et al 5
adipose depot; it is plausible that other fat depots responded
diﬀerently. In the light of an almost 2-fold increase in plasma
insulin levels, it was surprising that adiponectin and resistin
did not diﬀer between WT and aP2-Agt mice. This may indi-
cate diﬀerential sensitivity of diﬀerent metabolic markers to
Agt manipulation. Further studies will be necessary to deter-
mine the basis for this unexpected response.
Despite diﬀerences in insulin levels, plasma glucose was
not statistically impacted by genotype (not shown). One po-
tential explanation is that the hyperinsulinemia of aP2-WT
mice is suﬃcient to maintain euglycemia. Conversely, Agt-
KO mice maintain euglycemia because of increased insulin
sensitivity and a concomitant reduction in insulin secretion.
Theseﬁndingsneedtobefurtherexploredusingthoroughin
vivo measures of insulin sensitivity and glucose tolerance.
Our second goal was to determine how altering adipose
Agt production impacted RAS regulation distally through
endocrine actions, as Ang II exerts various eﬀects on the ex-
pression of major component genes of the RAS by feedback
mechanisms [28,29,35–37].Wefocusedonkidney duetoits
primary role in blood pressure regulation and the fact that
aP2-Agt mice are hypertensive. We found that AGTR1 pro-
tein was lower in Agt-KO mice than in wild type. This con-
trasts with a previous report showing upregulation of renal
Agtr1 mRNA and protein expression in Agt-KO mice, rais-
ing the possibility that diﬀerences in RAS regulation in Agt
null mice may also be associated with genetic background
[37, 38]. We also found that renal levels of AGTR1 were
signiﬁcantly increased in aP2-Agt mice compared with WT
mice, a result that is somewhat surprising in light of the fact
that chronic Ang II infusion in rats did not alter whole kid-
ney AGTR1 content [39]. Although we did not speciﬁcally
measure plasma Ang II concentrations in the current study,
we predict that they would be elevated due to the increase in
circulating AGT levels and the fact that aP2-Agt mice are hy-
pertensive [6]. In contrast, the observation that renal AGTR2
receptor protein expression was not altered in response to el-
evated Agt was expected [39].
Multiple studies have demonstrated a somewhat para-
doxical regulation of Agt by Ang II, in which hormone sub-
strate levels are actually increased at both the mRNA and
protein levels by bioactive hormone. We demonstrate here
that elevating adipose Agt expression activates AGT synthe-
sis in kidney, presumably due to an increase in plasma Ang
II [40]. Although not explicitly measured, we expect that the
increase in renal Agt expression translates into elevated in-
trarenal Ang II content, which, coupled with increased renal
AGTR1, may contribute to the hypertension documented in
aP2-Agt mice [41–43]. Brain-speciﬁc overexpression of Agt
also has been shown to increase blood pressure [38]. There-
foreitisplausiblethathypertensionofaP2-Agt miceisdueto
one or a combination of elevated circulating Ang II, activa-
tion of the intrarenal RAS Ang II, and/or activation of other
local RAS such as that in the brain. Further studies will be
necessary to determine the contribution(s) of each of these
tissues and the mechanisms mediating this regulation.
In conclusion, we have demonstrated that the adi-
pose RAS extends its physiological actions well beyond the
local environment of the adipocyte, impacting maintenance
of blood pressure and insulin sensitivity in the whole animal.
Given that RAS activity in adipose tissue varies with adipos-
ity, these ﬁndings highlight the potential role played by the
adipose RAS in the metabolic syndrome and underscore the
importance of continued investigation into this possibility.
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